Bernard Ross, CEO of Sky Medical Technology, outlines how the NHS can ease pressures in chronic wound care management.

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

BioStem Technologies has agreed to acquire BioTissue Holdings’ surgical and wound care business, expanding the former company’s existing wound care product range in a deal worth up to $40m. BioStem ...

Chronic wounds, like pressure injuries and diabetic foot ulcers, affect more than 6 million people in the U.S.1 When these wounds don’t heal properly, they can lead to serious complications requiring ...

A growing body of research, as well as first-hand accounts from clinicians on the ground, indicate that a significant percentage of patients with chronic wounds have delayed preventative and emergent ...

BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative ...

The debilitating pain kept growing. Following hysterectomy surgery in August 2021, Aleisha Hennsley found the area around the incision to grow swollen, aching and increasingly infected. The agony ...

An estimated 10.5 million people across the U.S. live with chronic wounds that are difficult to heal.

Key Players Covered in the Smith & Nephew (U.K.), mölnlycke Health Care AB (Sweden), 3M (U.S.), ConvaTec Group PLC (U.K.), Tissue Regenix (U.S.), B. Braun Melsungen AG (Germany), Integra LifeSciences ...